Get access

Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue

Authors

  • Valérie Cochen MD,

    1. Unité de Recherche Associée Commissariat à l'Energie Atomique (CEA)–Centre National de la Recherche Scientifique (CNRS) 2210, Orsay, France
    Search for more papers by this author
  • Maria-Joao Ribeiro MD, PhD,

    1. CEA, Direction des Sciences du Vivant/Département de Recherche Médicale, Service Hospitalier Frédéric Joliot, Orsay, France
    Search for more papers by this author
  • Jean-Paul Nguyen MD,

    1. Département de Neurosciences, Centre Hospitalier Universitaire (CHU) Henri Mondor, AP-HP et Faculté de Médecine Paris-XII, Créteil, France
    2. Institut National de la Santé et de la Recherche Médicale U421, Faculté de Médecine, Créteil, France
    Search for more papers by this author
  • Jean-Marc Gurruchaga MD,

    1. Département de Neurosciences, Centre Hospitalier Universitaire (CHU) Henri Mondor, AP-HP et Faculté de Médecine Paris-XII, Créteil, France
    Search for more papers by this author
  • Gabriel Villafane MD,

    1. Département de Neurosciences, Centre Hospitalier Universitaire (CHU) Henri Mondor, AP-HP et Faculté de Médecine Paris-XII, Créteil, France
    Search for more papers by this author
  • Christian Loc'h BS,

    1. CEA, Direction des Sciences du Vivant/Département de Recherche Médicale, Service Hospitalier Frédéric Joliot, Orsay, France
    Search for more papers by this author
  • Gilles Defer MD,

    1. Département de Neurosciences, Centre Hospitalier Universitaire (CHU) Henri Mondor, AP-HP et Faculté de Médecine Paris-XII, Créteil, France
    2. Service de Neurologie Déjerine, Caen, France
    Search for more papers by this author
  • Yves Samson MD,

    1. CEA, Direction des Sciences du Vivant/Département de Recherche Médicale, Service Hospitalier Frédéric Joliot, Orsay, France
    2. Urgences Cérébro-Vasculaires, CHU Pitié-Salpétrière, Paris, France
    Search for more papers by this author
  • Marc Peschanski MD, PhD,

    1. Département de Neurosciences, Centre Hospitalier Universitaire (CHU) Henri Mondor, AP-HP et Faculté de Médecine Paris-XII, Créteil, France
    2. Institut National de la Santé et de la Recherche Médicale U421, Faculté de Médecine, Créteil, France
    Search for more papers by this author
  • Philippe Hantraye PhD,

    1. Unité de Recherche Associée Commissariat à l'Energie Atomique (CEA)–Centre National de la Recherche Scientifique (CNRS) 2210, Orsay, France
    Search for more papers by this author
  • Pierre Cesaro MD, PhD,

    1. Département de Neurosciences, Centre Hospitalier Universitaire (CHU) Henri Mondor, AP-HP et Faculté de Médecine Paris-XII, Créteil, France
    2. Institut National de la Santé et de la Recherche Médicale U421, Faculté de Médecine, Créteil, France
    Search for more papers by this author
  • Philippe Remy MD, PhD

    Corresponding author
    1. Unité de Recherche Associée Commissariat à l'Energie Atomique (CEA)–Centre National de la Recherche Scientifique (CNRS) 2210, Orsay, France
    2. CEA, Direction des Sciences du Vivant/Département de Recherche Médicale, Service Hospitalier Frédéric Joliot, Orsay, France
    3. Département de Neurosciences, Centre Hospitalier Universitaire (CHU) Henri Mondor, AP-HP et Faculté de Médecine Paris-XII, Créteil, France
    • URA CEA-CNRS 2210, Service Hospitalier Frédéric Joliot, 91401 Orsay Cedex, France
    Search for more papers by this author

Abstract

An erratum for this article appears in the January, 2004 issue of Movement Disorders (Mov Disord 2004;12:119).

We compared the striatal uptake of [18F]fluorodopa with [76Br]-FE-CBT, a positron emission tomography (PET) ligand of the dopamine transporter (DAT), which estimates the density of dopamine nerve terminals, in 6 patients with Parkinson's disease grafted with fetal mesencephalic cells. There was no change in DAT ligand binding in the grafted putamen, despite a significant increase of [18F]fluorodopa uptake. This finding suggests that the clinical benefit induced by the graft is more related to increased dopaminergic activity than improved dopaminergic innervation in the host striatum and, therefore, that [18F]fluorodopa remains the optimal tracer to evaluate grafted PD patients. Further analysis showed that the clinical and [18F]fluorodopa uptake changes after the grafts were correlated with the number of ventral mesencephalae used for implantation. © 2003 Movement Disorder Society

Ancillary